Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek B Lowe

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|September 17, 2025
Mimicking Complex Receptor Actions with Small(ish) MoleculesDerek B Lowe
ACS Medicinal Chemistry Letters|June 6, 2014
Nowhere to go but up: the return of medicinal chemistryDerek B Lowe
Nature Chemistry|September 23, 2014
Drug discovery: Combichem all over againDerek B Lowe
Biochemistry|February 7, 2018
Introducing Biochemistry to BedsideDerek B Lowe
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2005
Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucoseThomas H Claus, Derek B Lowe, Yin Liang, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipaseDerek B Lowe, Steven Magnuson, Ning Qi, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Substituted indanylacetic acids as PPAR-alpha-gamma activatorsDerek B Lowe, Neil Bifulco, William H Bullock, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidateJill Wood, Cedo M Bagi, Christiana Akuche, et al.
Journal of Medicinal Chemistry|May 31, 2018
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)Jon H Come, Philip N Collier, James A Henderson, et al.
Journal of Medicinal Chemistry|September 25, 2007
Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesityJoachim Rudolph, William P Esler, Stephen O'connor, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|September 17, 2025
Mimicking Complex Receptor Actions with Small(ish) MoleculesDerek B Lowe
ACS Medicinal Chemistry Letters|June 6, 2014
Nowhere to go but up: the return of medicinal chemistryDerek B Lowe
Nature Chemistry|September 23, 2014
Drug discovery: Combichem all over againDerek B Lowe
Biochemistry|February 7, 2018
Introducing Biochemistry to BedsideDerek B Lowe
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2005
Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucoseThomas H Claus, Derek B Lowe, Yin Liang, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipaseDerek B Lowe, Steven Magnuson, Ning Qi, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Substituted indanylacetic acids as PPAR-alpha-gamma activatorsDerek B Lowe, Neil Bifulco, William H Bullock, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidateJill Wood, Cedo M Bagi, Christiana Akuche, et al.
Journal of Medicinal Chemistry|May 31, 2018
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)Jon H Come, Philip N Collier, James A Henderson, et al.
Journal of Medicinal Chemistry|September 25, 2007
Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesityJoachim Rudolph, William P Esler, Stephen O'connor, et al.
Pageof 1